

combination therapies with a correction-free and heart rate-free method. *Scientific Reports*. 2019;9(1):883.

54. Buckingham R. Martindale. The complete drug reference. 40th edition. London (UK): Pharmaceutical Press; 2020.

55. Traevert M, Dumotier B. Antimalarial drugs: QT prolongation and cardiac arrhythmias. *Expert Opin Drug Saf*. 2005;4(3):421-431.

56. Bouchaud O, Imbert P, Touze JE, et al. Fatal cardiotoxicity related to halofantrine: a review based on a worldwide safety data base. *Malar J*. 2009;8:289.

57. Millat-Martínez P, Salman S, Moore BR, et al. Piperazine Pharmacokinetic and Pharmacodynamic Profiles in Healthy Volunteers of Papua New Guinea after Administration of Three-Monthly Doses of Dihydroartemisinin-Piperazine. *Antimicrob Agents Chemother*. 2022;66(8):e0018522.

58. Esposito S, Bianchini S, Blasi F. Bedaquiline and delamanid in tuberculosis. *Expert Opin Pharmacother*. 2015;16(15):2319-2330.

59. Pontali E, Sotgiu G, Tiberi S, et al. Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence. *Eur Respir J*. 2017;50(5).

60. Kwon YS, Jeong BH, Koh WJ. Delamanid when other anti-tuberculosis-treatment regimens failed due to resistance or tolerability. *Expert Opin Pharmacother*. 2015;16(2):253-261.

61. Anand AB, Malur K, Sabnis GR, et al. A case series of drug-induced torsades de pointes in patients on multidrug-resistant tuberculosis treatment: Beware the gift that conceals a blade. *Heart Rhythm O2*. 2024;5(5):324-326.

62. Le Blaye I, Donatini B, Hall M, et al. Acute overdosage with thioridazine: a review of the available clinical exposure. *Vet Hum Toxicol*. 1993;35(2):147-150.

63. Isbister GK, Balit CR, Macleod D, et al. Amisulpride overdose is frequently associated with QT prolongation and torsades de pointes. *J Clin Psychopharmacol*. 2010;30(4):391-395.

64. Wenzel-Seifert K, Wittmann M, Haen E. QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes. *Dtsch Arztebl Int*. 2011;108(41):687-693.

65. Hassaballa HA, Balk RA. Torsade de pointes associated with the administration of intravenous haloperidol. *Am J Ther*. 2003;10(1):58-60.

66. Nuttall GA, Eckerman KM, Jacob KA, et al. Does low-dose droperidol administration increase the risk of drug-induced QT prolongation and torsade de pointes in the general surgical population? *Anesthesiology*. 2007;107(4):531-536.

67. Lischke V, Behne M, Doelken P, et al. Droperidol causes a dose-dependent prolongation of the QT interval. *Anesth Analg*. 1994;79(5):983-986.

68. Tampi RR, Balderas M, Carter KV, et al. Citalopram, QTc Prolongation, and Torsades de Pointes. *Psychosomatics*. 2015;56(1):36-43.

69. Kumar S, Gayle JA, Mogalapalli A, et al. Escitalopram Induced Torsade de Pointes and Cardiac Arrest in a Patient With Surgi-

cally Treated Mitral Valve Prolapse. *Cureus*. 2020;12(12):e11960.

70. Lingyan G, Dongdong Z, Sang G, et al. Escitalopram-induced prolongation of QT interval and Torsades de Pointes. *Adverse Drug Reactions Journal*. 2020;22(12):695-696.

71. de Meester A, Carbutti G, Gabriel L, et al. Fatal overdose with trazodone: case report and literature review. *Acta Clin Belg*. 2001;56(4):258-261.

72. Khederlou H, Azimi Pirsaravi V. Torsades de Pointe Associated with Trazodone Consumption Case Rep Crit Care. 2024;2024:5759229.

73. Giroski L, Shih R. QTc Prolongation and Torsades in Bupropion Overdoses Presenting to United States Emergency Departments. *Journal of Emergency Medicine*. 2012;43(5):934-935.

74. Isbister GK, Balit CR. Bupropion overdose: QTc prolongation and its clinical significance. *Ann Pharmacother*. 2003;37(7-8):999-1002.

75. Raffa RB, Burmeister JJ, Yuvashva E, et al. QTc interval prolongation by d-proproxyphene: what about other analgesics? *Expert Opin Pharmacother*. 2012;13(10):1397-1409.

76. Krantz MJ, Palmer RB, Haigney MCP. Cardiovascular Complications of Opioid Use: JACC State-of-the-Art Review. *J Am Coll Cardiol*. 2021;77(2):205-223.

77. Alinejad S, Kazemi T, Zamani N, et al. A systematic review of the cardiotoxicity of methadone. *EXCLI J*. 2015;14:577-600.

78. Ehret GB, Voide C, Gex-Fabry M, et al. Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors. *Arch Intern Med*. 2006;166(12):1280-1287.

79. Duthie DJ, McLaren AD, Nimmo WS. Pharmacokinetics of fentanyl during constant rate i.v. infusion for the relief of pain after surgery. *Br J Anaesth*. 1986;58(9):950-956.

80. Cicci JD, Jagielski SM, Clarke MM, et al. Loperamide overdose causing torsades de pointes and requiring Impella temporary mechanical support: a case report. *Eur Heart J Case Rep*. 2019;3(4):1-6.

81. Marzec LN, Katz DF, Peterson PN, et al. Torsade de Pointes Associated with High-dose Loperamide Ingestion. *J Innov Card Rhythm Manag*. 2015;6(1):1897-1999.

82. Cirillo I, Ariyawansa J, Ali SR, et al. Effect of loperamide on heart rhythm: Randomized, double-blind, controlled study in healthy adults. *JAPhA Pharmacotherapy*. 2024;1(3):100006.

83. Shah RR, Morganroth J, Shah DR. Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval). *Drug Saf*. 2013;36(5):295-316.

84. Megias-Vericat JE, Solana-Altabella A, Ballesta-López O, et al. Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia. *Ann Hematol*. 2020;99(9):1989-2007.

85. Anand K, Ensor J, Trachtenberg B, et al. Osimertinib-Induced Cardiotoxicity: A Retrospective Review of the FDA Adverse Events Reporting System (FAERS). *JACC CardioOncol*.

2019;1(2):172-178.

86. Waliyan S, Zhu H, Wakelee H, et al. Pharmacovigilance Analysis of Cardiac Toxicities Associated With Targeted Therapies for Metastatic NSCLC. *J Thorac Oncol*. 2021;16(12):2029-2039.

87. Kang D, Ludwig E, Jaworowicz D, et al. Concentration-QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia. *Cancer Chemother Pharmacol*. 2021;87(4):513-523.

88. Loffi M, Toffetti L, Gianni C, et al. Self-Terminating Ventricular Fibrillation in Vandetanib-Induced Torsades de Pointes. *J Cardiovasc Electrophysiol*. 2015;26(7):811-813.

89. Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). *Eur Heart J*. 2022;43(41):4229-4361.

90. Giaccone G, Rajan A, Berman A, et al. Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. *J Clin Oncol*. 2011;29(15):2052-2059.

91. Shetty N, Gupta S. Eribulin drug review. *South Asian J Cancer*. 2014;3(1):57-59.

92. Fostvedt LK, Shaik N, Martinelli G, et al. Exposure-response modeling of the effect of glasdegib on cardiac repolarization in patients with cancer. *Expert Rev Clin Pharmacol*. 2021;14(7):927-935.

93. Vogel CL, Johnston MA, Capers C, et al. Toremifene for breast cancer: a review of 20 years of data. *Clin Breast Cancer*. 2014;14(1):1-9.

94. Flatman PW, Lev WL. The magnesium dependence of sodium-pump-mediated sodium-potassium and sodium-sodium exchange in intact human red cells. *J Physiol*. 1981;315:421-446.

95. Apell HJ, Hitzler T, Schreiber G. Modulation of the Na,K-ATPase by Magnesium Ions. *Biochemistry*. 2017;56(7):1005-1016.

96. Schwartz PJ, Crotti L. QTc behavior during exercise and genetic testing for the long-QT syndrome. *Circulation*. 2011;124(20):2181-2184.

97. Khatib R, Sabir FRN, Omari C, et al. Managing drug-induced QT prolongation in clinical practice. *Postgrad Med J*. 2021;97(1149):452-458.

98. Magyar J, Horváth B, Bányász T, et al. L-364,373 fails to activate the slow delayed rectifier K⁺ current in canine ventricular cardiomyocytes. *Naunyn Schmiedebergs Arch Pharmacol*. 2006;373(1):85-89.

99. Short B. A range of activators for cardiac IKs channels. *J Gen Physiol*. 2020;152(2).

100. Corici C, Kohajda Z, Kristóf A, et al. L-364,373 (R-L3) enantiomers have opposite modulating effects on IKs in mammalian ventricular myocytes. *Can J Physiol Pharmacol*. 2013;91(8):586-592.

S NÁMI SE NEZTRATÍTE

Časopis je indexován v databázích Scopus a Embase

Využíváme systém **CrossRef**. S články můžete snadno pracovat díky jednoznačnému identifikátoru **DOI**.

